PanCAN Statement on Positive Overall Survival Results from Revolution Medicines Phase III Trial at ASCO

The Pancreatic Cancer Action Network (PanCAN), the leading organization dedicated to advancing progress against pancreatic cancer, released a statement today following the full data from Revolution Medicines' global, randomized, controlled Phase 3 RASolute 302 clinical trial presented at the American Society of Clinical Oncology (ASCO) annual meeting.

"The results presented by Dr. Brian Wolpin at ASCO for daraxonrasib were jaw-dropping and represent the most significant advance we have ever seen in pancreatic cancer," said Anna Berkenblit, M.D., MMSc, Chief Scientific and Medical Officer, PanCAN. "For a disease that has long been marked by limited treatment options and often devastating outcomes, seeing a therapy double overall survival and progression-free survival and triple the response rate compared with standard of care chemotherapy in patients with previously treated metastatic pancreatic cancer is unprecedented. Importantly, patients also experienced improvement in pain and quality of life so that patients not only live longer but also feel better. Optimal management of side effects, including rash and mouth sores, will be paramount to maximize the benefit. We anticipate that daraxonrasib will become the new standard of care for previously treated metastatic pancreatic cancer.

"What an extraordinary privilege it was to be in the room where the data were presented, joining thousands of colleagues from across the cancer community in a standing ovation. Many have dedicated years of tireless work to this cause-and it was an honor to witness this moment together. The significance of this news and what it will mean for pancreatic cancer patients was deeply moving and brought tears to my eyes.

"Daraxonrasib was recently selected for the FDA Commissioner's National Priority Voucher pilot program, which is intended to accelerate the review of therapies aligned with U.S. national health priorities, and is currently available through an Expanded Access Program. We look forward to a speedy review and full approval by the FDA sometime this year.

"We thank Revolution Medicines for their commitment to science and patients and are especially grateful to the patients who participated in the clinical trial. While these results represent a huge step forward in the field, they are just the beginning. We know that resistance to treatment can develop, and research into drug combinations is ongoing to overcome these challenges. Clinical trials remain the best way to advance the field and discover new breakthroughs. Daraxonrasib is the most advanced RAS inhibitor in development for pancreatic cancer, with many others being studied as well, as single agents and in combinations. And as RASolute 302 was in patients with previously treated pancreatic cancer, we are excited about the prospect of moving RAS inhibitors into earlier treatment settings.

"PanCAN Patient Services Case Managers are standing by to provide information and resources to patients, including biomarker testing of tumor tissue and personalized clinical trials searches."

About Pancreatic Cancer
Pancreatic cancer is one of the most difficult cancers to detect and treat. It is the third leading cause of cancer-related deaths in the United States and is on track to become the second. With a five-year survival rate of only 13%, it remains the only major cancer whose survival rate is below 20%. Because symptoms are often vague and mimic other conditions, most patients are diagnosed in the later stages, when tumors are inoperable and treatment options are limited. Detecting the disease earlier, when surgery is possible, is critical to improving outcomes. There is no standard screening strategy for pancreatic cancer and few treatment options, highlighting the urgent need for increased funding and awareness to improve patient outcomes.

About the Pancreatic Cancer Action Network
The Pancreatic Cancer Action Network (PanCAN) is the leading organization dedicated to advancing progress against pancreatic cancer. We unite the pancreatic cancer community and push every boundary to create a world where survival is the expectation - not the exception. PanCAN empowers patients and caregivers with the resources and knowledge they need to advocate for the care they deserve. We are pioneering the advancement of an early detection strategy for pancreatic cancer and revolutionizing the development of advanced and personalized treatments; and we are building and mobilizing the pancreatic cancer field to ensure better outcomes for all those who face pancreatic cancer today and all those who will fight this disease tomorrow.

For more information, please contact: Julie Vasquez, Senior Director, Public Relations, 310-697-9129, [email protected]

Charaighn Sesock, Associate Director, Public Relations, 559-972-4877, [email protected]